Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Biomedical Engineering
SJR: 0.26 SNIP: 0.375 CiteScore™: 1.4

ISSN Imprimir: 0278-940X
ISSN On-line: 1943-619X

Volumes:
Volume 48, 2020 Volume 47, 2019 Volume 46, 2018 Volume 45, 2017 Volume 44, 2016 Volume 43, 2015 Volume 42, 2014 Volume 41, 2013 Volume 40, 2012 Volume 39, 2011 Volume 38, 2010 Volume 37, 2009 Volume 36, 2008 Volume 35, 2007 Volume 34, 2006 Volume 33, 2005 Volume 32, 2004 Volume 31, 2003 Volume 30, 2002 Volume 29, 2001 Volume 28, 2000 Volume 27, 1999 Volume 26, 1998 Volume 25, 1997 Volume 24, 1996 Volume 23, 1995

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.2014011578
pages 193-212

Drug-Coated Percutaneous Balloon Catheters

Jayesh V. Betala
Department of Bioengineering, Clemson University, Clemson, South Carolina
Eugene M. Langan III
Department of Vascular Surgery, Greenville Health System, Greenville, South Carolina
jayesh betala
Clemson University

RESUMO

Percutaneous transluminal angioplasty revolutionized coronary and peripheral revascularization. However, it is always accompanied by major drawbacks such as elastic recoil and neointimal hyperplasia. Percutaneous transluminal angioplasty along with bare metal stents reduced elastic recoil, but in-stent restenosis (ISR) and peripheral artery stenting remain problems. Drug-eluting stents addressed the issue of ISR, but late stent thrombosis and delayed endothelialization, along with longer dual antiplatelet therapy, are of concern. Non-stent-based delivery such as drug-coated balloons (DCBs) that can deliver drugs to inhibit ISR or to de novo lesions, are emerging at a rapid pace. DCBs carry an active drug and a nonpolymeric carrier molecule or excipient that enhance the bioavailability of the drug to the vessel wall. Preliminary studies of paclitaxel show sustained delivery is not required to inhibit proliferation of vascular smooth muscle cells, which leds to the development and evolution of DCBs. Recent clinical trials have been successful in mitigating ISR in coronary and peripheral arteries, but not in de novo lesions of coronary arteries. Clinical studies, although limited to date, show a promising future for DCBs.


Articles with similar content:

Phosphorylcholine-Coated Stents
Journal of Long-Term Effects of Medical Implants, Vol.12, 2002, issue 4
Andrew L. Lewis, Peter W. Stratford
A Review on Phosphorylcholine-Coated Stents
Journal of Long-Term Effects of Medical Implants, Vol.27, 2017, issue 2-4
Andrew L. Lewis, Peter W. Stratford
Enhancement of Transdermal Delivery of Heparin by Various Physical and Chemical Enhancement Techniques
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 6
S. S. Lanke, Ajay K. Banga, J. G. Strom
Antibodies and Peptides in Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 5
Tamara Minko, Jayant J. Khandare
Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 4
Munira Momin, Chintan Bhavsar, Sankalp A. Gharat